Squamous Cell Carcinoma of the Bladder Associated with Cyclophosphamide Therapy for Wegener’s Granulomatosis: A Report of 2 Cases
- 1 March 1993
- journal article
- case report
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 149 (3) , 588-589
- https://doi.org/10.1016/s0022-5347(17)36156-6
Abstract
Cyclophosphamide has been used to treat a variety of malignant and nonmalignant diseases. The association of this agent with the development of urothelial tumors has been well documented. Although most bladder cancers associated with prior cyclophosphamide therapy are transitional cell carcinoma, to our knowledge there have been 6 reports of cyclophosphamide-induced squamous cell carcinoma of the bladder. We report 2 additional cases of squamous cell carcinoma of the bladder that occurred in patients after cyclophosphamide treatment for Wegener's granulomatosis. Any patient with a history of prolonged cyclophosphamide ingestion needs careful long-term monitoring of the lower urinary tract, since there is at least a 9-fold increase in the incidence of lower urinary tract malignancy in such patients.Keywords
This publication has 16 references indexed in Scilit:
- Bladder malignancy in patient receiving cyclophosphamide for benign diseaseUrology, 1981
- The Incidence Of Bladder Cancer after Cyclophosphamide TherapyJournal of Urology, 1979
- Bladder Complications in Patients Receiving Cyclophosphamide for Systemic Lupus Erythematosus or Rheumatoid ArthritisAnnals of Internal Medicine, 1979
- Urological Complications of CyclophosphamideBritish Journal of Urology, 1973
- Cyclophosphamide and the bladder.BMJ, 1971
- Cyclophosphamide Therapy in Wegener's GranulomatosisNew England Journal of Medicine, 1971
- Urinary-Bladder Fibrosis and Telangiectasia Associated with Long-Term Cyclophosphamide TherapyNew England Journal of Medicine, 1971
- Hemorrhagic Cystitis Due to CyclophosphamideJournal of Urology, 1969
- Cyclophosphamide Hemorrhagic CystitisJournal of Urology, 1967
- Folgen am harnbereitenden und harnableitenden System während Cyclophosphamid-Therapie1Deutsche Medizinische Wochenschrift (1946), 1965